Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC.

Rosnev S, Klein K, Heukamp L, Lenk J, Joosten M, Möbs M, Grob T, Benary M, Vecchione L, Ott CE, Modest DP, Knödler M, Keller U, Frost N, Keilholz U, Kiewe P, Rieke DT

Open source

DOI: 10.1093/oncolo/oyag151
Published: 2026 May 8
Container: The oncologist
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyag151,
  title = {Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC.},
  author = {Rosnev S and Klein K and Heukamp L and Lenk J and Joosten M and Möbs M and Grob T and Benary M and Vecchione L and Ott CE and Modest DP and Knödler M and Keller U and Frost N and Keilholz U and Kiewe P and Rieke DT},
  year = {2026},
  journal = {The oncologist},
  doi = {10.1093/oncolo/oyag151},
  url = {https://doi.org/10.1093/oncolo/oyag151}
}

RIS

TY  - JOUR
TI  - Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC.
AU  - Rosnev S
AU  - Klein K
AU  - Heukamp L
AU  - Lenk J
AU  - Joosten M
AU  - Möbs M
AU  - Grob T
AU  - Benary M
AU  - Vecchione L
AU  - Ott CE
AU  - Modest DP
AU  - Knödler M
AU  - Keller U
AU  - Frost N
AU  - Keilholz U
AU  - Kiewe P
AU  - Rieke DT
PY  - 2026
JO  - The oncologist
DO  - 10.1093/oncolo/oyag151
UR  - https://doi.org/10.1093/oncolo/oyag151
ER  -

APA

S, R., K, K., L, H., J, L., M, J., M, M., T, G., M, B., L, V., CE, O., DP, M., M, K., U, K., N, F., U, K., P, K., & DT, R. (2026). Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC.. The oncologist. https://doi.org/10.1093/oncolo/oyag151

Source records

pubmed · retrieved 2026-09-26T22:29:46.987Z